Speedy NICE Support For Eisai's Lenvima In Liver Cancer
Executive Summary
It took NICE nearly three years to offer routine access to Lenvima for thyroid cancer but it has taken just three months from European approval to recommend the drug for advanced or unresectable hepatocellular carcinoma.
You may also be interested in...
Shionogi To Switch Europe HQ Out Of London Over Brexit
The drug maker looks set to join fellow Japanese firms Sony and Panasonic in moving its European legal base out of the UK as the uncertainties surrounding Brexit show little sign of being resolved.
Eisai Says Lenvatinib Lost in UK Market Access Maze Due To NICE Inaction
Japan's Eisai is considering all options including legal action and reducing its investment in the UK to force NICE to make its potential blockbuster TKI cancer drug lenvatinib available sooner to patients with advanced thyroid cancer via the publicly-funded National Health Service.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.